Slowing the development and progression of CKD remains an unmet clinical need in patients with T2D. This program supports pharmacists in ensuring their up-to-date knowledge of pharmacological options that have demonstrated nephroprotective effects in patients with T2D and CKD.
The efficacy, safety, and dosing of these nephroprotective medications will be illustrated through case-based learning, to increase pharmacists’ confidence in identifying patients in community practice who might benefit and recommending this class of medication.